Quarterly report pursuant to Section 13 or 15(d)

Restructuring Charges

v3.7.0.1
Restructuring Charges
6 Months Ended
Jun. 30, 2017
Restructuring Charges  
Restructuring Charges

13.Restructuring Charges

 

In September 2016, we announced that we had reduced our workforce by 46 positions, mostly in the research area.  We also announced that effective September 15, 2016, Donald G. Payan, M.D, retired from the board of directors and from his position as Executive Vice President and President of Discovery and Research. We recorded restructuring charges during the third quarter of 2016 of approximately $5.8 million, which included $5.0 million of severance costs paid in cash, $319,000 impairment of certain property and equipment, and $499,000 of non-cash stock-based compensation expense as a result of the modification of our former executive’s stock options. At June 30, 2017, the remaining accrued restructuring cost of $218,000 related to COBRA benefits and outplacement costs and is classified under Accrued Compensation in the Condensed Balance Sheet.